CRDL Q4 2025 Earnings Narrower Than Expected Loss as Cardiol Therapeutics Advances Clinical Pipeline Telomir Pharmaceuticals TELO Q4 2025 Earnings WiderthanExpected Loss Amid Ongoing Development CXDO Q1 2026 Earnings EPS Surprises 256 Above Estimates SU Q1 2026 Earnings Strong EPS Beat Highlights Operational Efficiency Amid Market Challenges APOS Q1 2026 Earnings Modest EPS Miss Amid Stable Bond Performance KLAR Q1 2026 Earnings Significant EPS Beat as Losses Narrow Sharply